Clinical trials: Treatment Resistant Depression, active
Treatment Resistant Depression
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to…
- Trial name
- TREASURE (NCT06781697)
- Testing
- Ketamine, Oculus VR headset
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression, Substance Use Disorders
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder…
- Trial name
- NCT07499583
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Indiana University
Depression - Major Depressive Disorder
Effect of Neurofeedback and TMS
The goal of this clinical trial is to is to learn whether adding EEG neurofeedback (NFB) to repetitive transcranial magnetic stimulation (rTMS) is safe and feasible for adults with major depressive disorder (MDD).
- Trial name
- NCT07892287
- Testing
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Late Life Depression (LLD), Depression - Major Depressive Disorder
Accelerated vs. Conventional Theta Burst Stimulation for Late-life Depression
The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where…
- Conditions
- Late Life Depression (LLD), Depression - Major Depressive Disorder, Depressive Disorder, Treatment-Resistant, Mood Disorders
- Trial name
- ACT-LLD (NCT06854367)
- Testing
- TBS
- Where
- 2 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Centre for Addiction and Mental Health
MDD, Severe Depression
Sensation Seeking and TMS Response in TRD
his real-world observational study examines whether sensation-seeking personality traits influence the clinical response to transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (TRD).
- Conditions
- MDD, Severe Depression, Major Depressive Episode
- Trial name
- NCT07889739
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Technical University of Munich
Treatment Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale…
- Trial name
- RECOVER (NCT03887715)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- 101 sites in United States
- Volunteers
- 6,800 people
- Sponsor
- LivaNova
Treatment Resistant Depression, Chronic Pain
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- TRANSCEND (NCT06518720)
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
The objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of the Motif eXternally powered Cortical Stimulation (XCS) System when used as indicated for treatment-resistant depression (TRD).
- Trial name
- RESONATE (NCT07594483)
- Testing
- Motif XCS System
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Motif Neurotech, Inc.
Treatment Resistant Depression
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- SYNVEST (NCT06512220)
- Testing
- Psilocybin 25 mg, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Treatment Resistant Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic…
- Trial name
- TRANSCEND (NCT06423430)
- Testing
- Active-stimulation
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Intravenous Ketamine for Treatment-Resistant Depression
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA…
- Trial name
- G2K (NCT06668571)
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
The goal of this clinical trial is to test whether a personalized approach to treatment selection improves symptoms in older adults with treatment-resistant depression.
- Conditions
- Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- BAARD (NCT07810738)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation
- Where
- 3 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder (MDD), Treatment Resistant Depression
EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression
The purpose of this research is to see if an experimental treatment for depression called intermittent theta burst stimulation (iTBS), a form of transcranial magnetic stimulation (TMS) can be improved for better results using…
- Conditions
- Major Depressive Disorder (MDD), Treatment Resistant Depression, Major Depression
- Trial name
- CLEOPATRA (NCT07862205)
- Testing
- MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Depression - Major Depressive Disorder, Treatment Resistant Depression
ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder
This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in…
- Trial name
- BRIGHT (NCT07474974)
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Polytechnic Institute of Porto
Bipolar Depression, Bipolar Disorder
Theta-Burst Stimulation for Bipolar Depression
The purpose of this trial is to determine if intermittent theta-burst stimulation (iTBS) can reduce the symptoms of depression in treatment-resistant bipolar disorder.
- Conditions
- Bipolar Depression, Bipolar Disorder, Treatment- Resistant Bipolar Disorder, Type 2 Bipolar Disorder
- Trial name
- TRIBE (NCT06370988)
- Testing
- iTBS Stimulation
- Where
- 2 sites in Canada
- Volunteers
- 124 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression, Suicide Risk
Long-term Observation of Participants With Mood Disorders
Background: More than 12,000 people have taken part in research at the Experimental Therapeutics \& Pathophysiology Branch at the National Institute of Mental Health Intramural Program.
- Trial name
- NCT04877977
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)